ROIV
Q4 2026 EPS Estimate
$-0.35
Nov 9, 2026 · Reports before open
Revenue Estimate
$3M
FY2030E EPS$1.56
FY2031E EPS$2.70

Analyst Sentiment

Wall St. Consensus
Buy
15 analysts·Moderate coverage
73
Score
14 Buy (93%)1 Hold (7%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1493%
Hold
17%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$36.00
-0.7%
Consensus
$41.00
+13.1%
Bull
$42.00
+15.8%
12-Month Target Range15 analysts
$36.00$41.00$42.00
Current $36.26Consensus
Current Price
$36.26
Upside to Consensus
$4.74

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+638.98%
EPS
FY2028
Rev+772.90%
EPS
FY2029
Rev+188.53%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2027EFY2028EFY2029EFY2030EFY2031E
Revenue Avg$67M$586M$1.69B$3.29B$4.77B
Low$19M$317M$978M$1.41B$2.04B
High$129M$781M$3.65B$7.35B$10.66B
EBITDA Avg$-40M$-352M$-1.01B$-1.97B$-2.86B
Low$-77M$-469M$-2.19B$-4.41B$-6.40B
High$-12M$-190M$-587M$-845M$-1.23B
EBIT Avg$-40M$-352M$-1.01B$-1.97B$-2.86B
Low$-77M$-469M$-2.19B$-4.41B$-6.40B
High$-12M$-190M$-587M$-845M$-1.23B
Net Income Avg$-1.03B$-1.11B$-232M$1.08B$1.87B
Low$-2.26B$-1.89B$-343M$278M$481M
High$-223M$-186M$389M$2.82B$4.88B
EPS Avg$-1.25$-1.05$-0.08$1.56$2.70
Low$-3.26$-2.73$-0.50$0.40$0.69
High$-0.32$-0.27$0.56$4.06$7.04
Analysts (Rev / EPS)8 / 37 / 38 / 64 / 23 / 3
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028
Revenue Avg$4M$12M$37M$27M$52M$95M$136M
Low$3M$7M$23M$17M$32M$59M$84M
High$6M$19M$58M$43M$82M$151M$215M
EBITDA Avg$-2M$-7M$-22M$-16M$-31M$-57M$-82M
Low$-4M$-11M$-35M$-26M$-49M$-91M$-129M
High$-2M$-4M$-14M$-10M$-19M$-35M$-50M
EBIT Avg$-2M$-7M$-22M$-16M$-31M$-57M$-82M
Low$-4M$-11M$-35M$-26M$-49M$-91M$-129M
High$-2M$-4M$-14M$-10M$-19M$-35M$-50M
Net Income Avg$-235M$-227M$-225M$-226M$-226M$-219M$-209M
Low$-413M$-398M$-395M$-397M$-397M$-384M$-367M
High$-118M$-114M$-113M$-113M$-113M$-110M$-105M
EPS Avg$-0.33$-0.31$-0.31$-0.31$-0.31$-0.30$-0.29
Low$-0.57$-0.55$-0.55$-0.55$-0.55$-0.53$-0.51
High$-0.16$-0.16$-0.16$-0.16$-0.16$-0.15$-0.15
Analysts (Rev / EPS)6 / 23 / 13 / 13 / 13 / 13 / 14 / 1

Earnings Surprises

Recent Analyst Actions

Aug 7, 2026H.C. Wainwright
Roivant Sciences price target raised to $41 from $34 at H.C. Wainwright
Target:$41.00
+16.7%from $35.12
May 26, 2026Guggenheim
Roivant Sciences price target raised to $36 from $30 at Guggenheim
Target:$36.00
+20.2%from $29.96
May 21, 2026Cowen & Co.
Roivant Sciences price target raised to $41 from $38 at TD Cowen
Target:$41.00
+27.4%from $32.18
May 21, 2026Leerink Partners
Roivant Sciences (ROIV) PT Raised to $42 at Leerink
Target:$42.00
+29.6%from $32.41
Apr 16, 2026Piper Sandler
Roivant Sciences assumed with an Overweight at Piper Sandler
Target:$40.00
+36.7%from $29.26
Mar 4, 2026H.C. Wainwright
Roivant Sciences (ROIV) PT Raised to $34 at H.C. Wainwright
Target:$34.00
+18.0%from $28.81
Feb 10, 2026H.C. Wainwright
Roivant Sciences price target raised to $33 from $26 at H.C. Wainwright
Target:$33.00
+19.3%from $27.67
Feb 9, 2026Jefferies
Roivant Sciences price target raised to $30 from $24 at Jefferies
Target:$30.00
+13.4%from $26.45
Feb 9, 2026Guggenheim
Roivant Sciences price target raised to $30 from $28 at Guggenheim
Target:$30.00
+16.2%from $25.82
Dec 18, 2025Guggenheim
Roivant Sciences price target raised to $28 from $25 at Guggenheim
Target:$28.00
+25.6%from $22.30
Dec 15, 2025Leerink Partners
Roivant Sciences (ROIV) PT Raised to $32 at Leerink Partners
Target:$32.00
+44.8%from $22.09
Dec 12, 2025H.C. Wainwright
Roivant Sciences price target raised to $26 from $23 at H.C. Wainwright
Target:$26.00
+21.1%from $21.46
Nov 14, 2025Guggenheim
Roivant Sciences (ROIV) PT Raised to $25 at Guggenheim
Target:$25.00
+21.6%from $20.56
Nov 11, 2025Leerink Partners
Roivant Sciences (ROIV) PT Raised to $29 at Leerink Partners
Target:$29.00
+37.0%from $21.17
Sep 18, 2025Jefferies
Roivant Sciences price target raised to $20 from $18 at Jefferies
Target:$20.00
+29.3%from $15.47
Sep 18, 2025Guggenheim
Roivant Sciences price target raised to $21 from $15 at Guggenheim
Target:$21.00
+37.8%from $15.24
Sep 18, 2025H.C. Wainwright
Roivant Sciences price target raised to $20 from $18 at H.C. Wainwright
Target:$20.00
+31.2%from $15.24
Oct 21, 2024Leerink Partners
Leerink Partners Reiterates Outperform Rating on Roivant Sciences (ROIV)
Target:$17.00
+42.6%from $11.92
Sep 19, 2024Goldman Sachs
Goldman Sachs Reiterates Buy Rating on Roivant Sciences (ROIV)
Target:$17.00
+41.0%from $12.05
Sep 11, 2024Bank of America Securities
Roivant Sciences (ROIV) PT Raised to $12.50 at BofA Securities
Target:$12.50
+0.4%from $12.46
May 31, 2024Piper Sandler
Piper Sandler Reiterates Overweight Rating on Roivant Sciences (ROIV)
Target:$20.00
+92.5%from $10.39
Apr 3, 2024H.C. Wainwright
Roivant Sciences (ROIV) PT Raised to $18 at H.C. Wainwright, 'brepocitinib has blockbuster potential'
Target:$18.00
+64.8%from $10.92
Apr 3, 2024Deutsche Bank
Roivant Sciences price target raised to $15 from $14 at Deutsche Bank
Target:$15.00
+37.4%from $10.92
Apr 2, 2024Goldman Sachs
Roivant Sciences (ROIV) PT Raised to $18 at Goldman Sachs
Target:$18.00
+64.8%from $10.92
Mar 13, 2024Goldman Sachs
Roivant Sciences (ROIV) PT Raised to $16 at Goldman Sachs
Target:$16.00
+50.7%from $10.62
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.